About all

Breast Vibration and Cancer: Exploring the Potential of Mechanical Stimulation in Oncology

by alexxlab

How does breast vibration impact cancer progression. Can mechanical stimulation affect bone health in cancer patients. What are the potential therapeutic applications of vibration in oncology. Is low-magnitude high-frequency vibration beneficial for bone density

Содержание

The Link Between Breast Cancer and Bone Metastasis

Breast cancer remains one of the most prevalent forms of cancer worldwide, with a significant tendency to metastasize to bone. This propensity for bone metastasis presents unique challenges in treatment and patient care. Understanding the mechanisms behind this process is crucial for developing effective interventions.

Bone metastasis occurs when cancer cells from the breast migrate to the bone tissue, often leading to severe complications such as bone pain, fractures, and hypercalcemia. The bone microenvironment provides a fertile ground for cancer cell growth, creating a vicious cycle of bone destruction and tumor proliferation.

Why does breast cancer often spread to bones?

Several factors contribute to the high incidence of bone metastasis in breast cancer:

  • The rich blood supply in bone tissue
  • The presence of growth factors in the bone microenvironment
  • The ability of cancer cells to interact with bone cells, particularly osteoclasts and osteoblasts
  • The expression of specific proteins that allow cancer cells to adhere to bone tissue

Understanding these mechanisms has led researchers to explore novel approaches to prevent and treat bone metastasis in breast cancer patients.

Mechanical Stimulation and Its Effects on Bone Health

Recent studies have shed light on the potential benefits of mechanical stimulation, particularly vibration, on bone health. This emerging field of research has implications not only for general bone health but also for cancer-related bone complications.

Mechanical stimulation, in the form of low-magnitude high-frequency vibration (LMHFV), has shown promising results in improving bone density and strength. This non-invasive approach works by stimulating osteocytes, the mechanosensory cells in bone tissue, which in turn regulate bone formation and resorption.

How does mechanical stimulation affect bone tissue?

The effects of mechanical stimulation on bone tissue are multifaceted:

  1. Increased osteoblast activity, promoting bone formation
  2. Reduced osteoclast activity, decreasing bone resorption
  3. Enhanced blood flow to bone tissue
  4. Stimulation of mechanosensitive pathways in bone cells
  5. Improved overall bone microarchitecture

These effects collectively contribute to improved bone health and may have implications for preventing or mitigating bone metastasis in cancer patients.

Vibration Therapy in Cancer Treatment: Current Evidence

The application of vibration therapy in cancer treatment, particularly for bone metastasis, is an area of growing interest. Several studies have explored the potential benefits of this approach in both prevention and treatment contexts.

One notable study by Lynch et al. (2013) demonstrated that in vivo tibial compression could decrease osteolysis and tumor formation in a human metastatic breast cancer model. This groundbreaking research suggests that mechanical loading of bone tissue may have direct anti-tumor effects.

Can vibration therapy reduce cancer progression in bone?

While research is still ongoing, several studies have shown promising results:

  • Reduction in tumor size in animal models
  • Decreased osteolytic activity in metastatic lesions
  • Improved bone density in cancer patients undergoing treatment
  • Potential enhancement of chemotherapy efficacy when combined with vibration therapy

These findings suggest that vibration therapy could be a valuable adjunct to conventional cancer treatments, particularly in managing bone metastasis.

Low-Magnitude High-Frequency Vibration: A Promising Approach

Among the various forms of mechanical stimulation, low-magnitude high-frequency vibration (LMHFV) has emerged as a particularly promising approach. This technique involves applying gentle vibrations to the body at high frequencies, typically in the range of 20-100 Hz.

LMHFV has shown benefits in various populations, including postmenopausal women, childhood cancer survivors, and individuals with osteoporosis. Its non-invasive nature and relatively low risk of side effects make it an attractive option for potential integration into cancer care protocols.

What are the potential benefits of LMHFV in cancer patients?

The application of LMHFV in cancer patients may offer several advantages:

  • Improved bone mineral density
  • Enhanced muscle strength and function
  • Reduced risk of fractures
  • Potential reduction in cancer-related fatigue
  • Improved overall quality of life

These benefits could be particularly valuable for patients undergoing cancer treatment, who often experience significant bone loss and muscle weakness as side effects of their therapy.

Mechanisms of Action: How Vibration Affects Cancer Cells

The precise mechanisms by which vibration therapy affects cancer cells and bone metastasis are still being elucidated. However, several theories have been proposed based on current research findings.

One potential mechanism involves the activation of mechanosensitive pathways in both bone cells and cancer cells. This activation may lead to changes in gene expression and cellular behavior that are unfavorable to cancer progression.

How does vibration influence cancer cell behavior in bone?

Several potential mechanisms have been identified:

  1. Alteration of the bone microenvironment, making it less hospitable to cancer cells
  2. Disruption of cancer cell adhesion to bone tissue
  3. Modulation of inflammatory responses in the bone marrow
  4. Enhancement of immune cell function in the bone microenvironment
  5. Alteration of blood flow patterns, potentially affecting cancer cell extravasation

These mechanisms collectively contribute to the potential anti-tumor effects of vibration therapy in the context of bone metastasis.

Clinical Applications and Future Directions

While the potential of vibration therapy in cancer treatment is exciting, it’s important to note that much of the current evidence comes from preclinical studies and small clinical trials. Larger, well-designed clinical studies are needed to fully establish the efficacy and safety of this approach in cancer patients.

Nevertheless, the existing evidence suggests several potential clinical applications for vibration therapy in oncology:

How might vibration therapy be integrated into cancer care?

Potential applications include:

  • Prevention of cancer-related bone loss during treatment
  • Adjunct therapy for patients with established bone metastasis
  • Rehabilitation tool for cancer survivors to improve bone and muscle health
  • Potential enhancement of conventional therapies when used in combination

As research in this field progresses, we may see vibration therapy becoming an integral part of comprehensive cancer care protocols, particularly for patients at high risk of bone metastasis.

Safety Considerations and Patient Selection

While vibration therapy has shown promise in various studies, it’s crucial to consider safety aspects and appropriate patient selection. Not all patients may be suitable candidates for this type of intervention, and careful assessment is necessary before implementing vibration therapy.

Factors to consider include the patient’s overall health status, the extent of bone metastasis, and any contraindications to mechanical stimulation. Additionally, the optimal parameters for vibration therapy (frequency, amplitude, duration) may vary depending on the specific clinical context.

Who are ideal candidates for vibration therapy in cancer care?

Potential candidates may include:

  • Patients with early-stage breast cancer at risk of bone metastasis
  • Cancer survivors experiencing treatment-related bone loss
  • Patients with stable bone metastases who have completed primary treatment
  • Individuals undergoing hormone therapy with increased risk of osteoporosis

It’s important to note that vibration therapy should always be used under medical supervision and in conjunction with standard cancer treatments, not as a replacement for established therapies.

Combining Vibration Therapy with Other Interventions

The potential of vibration therapy in cancer care becomes even more intriguing when considered in combination with other interventions. Researchers are exploring how mechanical stimulation might enhance the efficacy of conventional cancer treatments or mitigate their side effects.

For instance, some studies suggest that vibration therapy may improve the delivery of chemotherapy drugs to tumor sites by altering blood flow patterns. Additionally, it may help counteract the bone loss often associated with hormone therapies used in breast cancer treatment.

How can vibration therapy complement existing cancer treatments?

Potential synergistic effects include:

  1. Enhanced drug delivery to tumor sites
  2. Mitigation of treatment-related bone loss
  3. Improved physical function and quality of life during treatment
  4. Potential reduction in treatment-related fatigue
  5. Enhancement of immune system function

These potential benefits highlight the importance of considering vibration therapy as part of a comprehensive, multi-modal approach to cancer care.

As research in this field continues to evolve, we may see the development of tailored protocols that combine vibration therapy with other interventions to optimize outcomes for cancer patients. This integrative approach could potentially improve both the efficacy of cancer treatments and the overall well-being of patients throughout their cancer journey.

The intersection of mechanical stimulation and cancer biology represents a fascinating frontier in oncology research. While much remains to be learned, the potential of vibration therapy to impact cancer progression and improve patient outcomes is an exciting prospect. As we continue to unravel the complex interactions between mechanical forces and cellular behavior, we may unlock new avenues for preventing and treating cancer, particularly in the context of bone metastasis.

Future research directions in this field are likely to focus on optimizing vibration parameters for specific clinical scenarios, exploring combination therapies, and conducting larger-scale clinical trials to establish efficacy and safety. Additionally, investigating the molecular mechanisms underlying the effects of vibration on cancer cells and the bone microenvironment will be crucial for refining and targeting this approach.

As we advance our understanding of the role of mechanical stimulation in cancer biology, we may be on the cusp of a new era in cancer care—one that harnesses the power of physical forces to complement and enhance our existing therapeutic arsenal. The potential to improve outcomes and quality of life for cancer patients through non-invasive, mechanically-based interventions is a compelling goal that warrants continued scientific exploration and clinical investigation.

Reduction of breast cancer extravasation via vibration activated osteocyte regulation

1. Lipton A., Uzzo R., Amato R.J., Ellis G.K., Hakimian B., Roodman G.D., Smith M.R. The science and practice of bone health in oncology: managing bone loss and metastasis in patients with solid tumors. J. Natl. Compr. Canc. Netw. 2009;7:1–29. doi: 10.6004/jnccn.2009.0080. quiz S30. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

2. Coughlin T.R., Romero-Moreno R., Mason D.E., Nystrom L., Boerckel J.D., Niebur G., Littlepage L.E. Bone: a fertile soil for cancer metastasis. Curr. Drug Targets. 2017;18:1281–1295. doi: 10.2174/1389450117666161226121650. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

3. Shemanko C.S., Cong Y., Forsyth A. What is breast in the bone? Int. J. Mol. Sci. 2016;17:1764. doi: 10.3390/ijms17101764. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

4. Gdowski A.S., Ranjan A., Vishwanatha J.K. Current concepts in bone metastasis, contemporary therapeutic strategies and ongoing clinical trials. J. Exp. Clin. Cancer Res. 2017;36:108–113. doi: 10.1186/s13046-017-0578-1. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

5. Sheill G., Guinan E.M., Peat N., Hussey J. Considerations for exercise prescription in patients with bone metastases: a comprehensive narrative review. PM R. 2018;10:843–864. doi: 10.1016/J.PMRJ.2018.02.006. [PubMed] [CrossRef] [Google Scholar]

6. Lynch M.E., Brooks D., Mohanan S., Lee M.J., Polamraju P., Dent K., Bonassar L.J., Van Der Meulen M.C.H., Fischbach C. In vivo tibial compression decreases osteolysis and tumor formation in a human metastatic breast cancer model. J. Bone Miner. Res. 2013;28:2357–2367. doi: 10.1002/jbmr.1966. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

7. Wang S., Pei S., Wasi M., Parajuli A., Yee A., You L., Wang L. Moderate tibial loading and treadmill running, but not overloading, protect adult murine bone from destruction by metastasized breast cancer. Bone. 2021;153:116100. doi: 10.1016/j.bone. 2021.116100. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

8. Mogil R.J., Kaste S.C., Ferry R.J., Hudson M.M., Mulrooney D.A., Howell C.R., Partin R.E., Srivastava D.K., Robison L.L., Ness K.K. Effect of low-magnitude, high-frequency mechanical stimulation on BMD among young childhood cancer survivors a randomized clinical trial. JAMA Oncol. 2016;2:908–914. doi: 10.1001/jamaoncol.2015.6557. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

9. Marín-Cascales E., Alcaraz P.E., Ramos-Campo D.J., Martinez-Rodriguez A., Chung L.H., Rubio-Arias J. Whole-body vibration training and bone health in postmenopausal women: a systematic review and meta-analysis. Medicine. 2018;97:e11918. doi: 10.1097/MD.0000000000011918. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

10. Oliveira L.C., Oliveira R.G., Pires-Oliveira D.A.A. Effects of whole body vibration on bone mineral density in postmenopausal women: a systematic review and meta-analysis. Osteoporos. Int. 2016;27:2913–2933. doi: 10.1007/s00198-016-3618-3. [PubMed] [CrossRef] [Google Scholar]

11. Rubin C., Recker R., Cullen D., Ryaby J., McCabe J., McLeod K. Prevention of postmenopausal bone loss by a low-magnitude, high-frequency mechanical stimuli: a clinical trial assessing compliance, efficacy, and safety. J. Bone Miner. Res. 2004;19:343–351. doi: 10.1359/JBMR.0301251. [PubMed] [CrossRef] [Google Scholar]

12. Liang Y.Q., Qi M.C., Xu J., Xu J., Liu H.W., Dong W., Li J.Y., Hu M. Low-magnitude high-frequency loading, by whole-body vibration, accelerates early implant osseointegration in ovariectomized rats. Mol. Med. Rep. 2014;10:2835–2842. doi: 10.3892/mmr.2014.2597. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

13. Vanleene M., Shefelbine S.J. Therapeutic impact of low amplitude high frequency whole body vibrations on the osteogenesis imperfecta mouse bone. Bone. 2013;53:507–514. doi: 10.1016/j.bone.2013.01.023. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

14. Rubin C., Turner A.S., Bain S., Mallinckrodt C., McLeod K. Low mechanical signals strengthen long bones. Nature. 2001;412:603–604. [PubMed] [Google Scholar]

15. Rubin C., Turner A.S., Müller R., Mittra E., McLeod K., Lin W., Qin Y.X. Quantity and quality of trabecular bone in the femur are enhanced by a strongly anabolic, noninvasive mechanical intervention. J. Bone Miner. Res. 2002;17:349–357. doi: 10.1359/jbmr.2002.17.2.349. [PubMed] [CrossRef] [Google Scholar]

16. Shi H.F., Cheung W.H., Qin L., Leung A.H.C., Leung K.S. Low-magnitude high-frequency vibration treatment augments fracture healing in ovariectomy-induced osteoporotic bone. Bone. 2010;46:1299–1305. doi: 10.1016/j.bone.2009.11.028. [PubMed] [CrossRef] [Google Scholar]

17. Baker M.K., Peddle-McIntyre C.J., Galvão D.A., Hunt C., Spry N., Newton R.U. Whole body vibration exposure on markers of bone turnover, body composition, and physical functioning in breast cancer patients receiving aromatase inhibitor therapy: a randomized controlled trial. Integr. Cancer Ther. 2018;17:968–978. doi: 10.1177/1534735418781489. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

18. Varghese F., Wong J. Breast cancer in the elderly. Surg. Clin. North Am. 2018;98:819–833. doi: 10.1016/j.suc.2018.04.002. [PubMed] [CrossRef] [Google Scholar]

19. Lynch M.A., Brodt M.D., Silva M.J. Skeletal effects of whole-body vibration in adult and aged mice. J. Orthop. Res. 2010;28:241–247. doi: 10.1002/jor.20965. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

20. Hemmatian H., Bakker A.D., Klein-Nulend J., van Lenthe G.H. Aging, osteocytes, and mechanotransduction. Curr. Osteoporos. Rep. 2017;15:401–411. doi: 10.1007/s11914-017-0402-z. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

21. Schurman C.A., Verbruggen S.W., Alliston T. Disrupted osteocyte connectivity and pericellular fluid flow in bone with aging and defective TGF- β signaling. Proc. Natl. Acad. Sci. USA. 2021;118 doi: 10.1073/pnas.2023999118. e2023999118. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

22. Yee C.S., Schurman C.A., White C.R., Alliston T. Investigating osteocytic perilacunar/canalicular remodeling. Curr. Osteoporos. Rep. 2019;17:157–168. doi: 10.1007/s11914-019-00514-0. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

23. Li X., Han L., Nookaew I., Mannen E., Silva M.J., Almeida M., Xiong J. Stimulation of piezo1 by mechanical signals promotes bone anabolism. Elife. 2019;8:e49631. doi: 10.7554/eLife.49631. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

24. Sun W., Chi S., Li Y., Ling S., Tan Y., Xu Y., Jiang F., Li J., Liu C., Zhong G., et al. The mechanosensitive Piezo1 channel is required for bone formation. Elife. 2019;8:e47454. doi: 10.7554/eLife.47454. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

25. Bonewald L.F. The amazing osteocyte. J. Bone Miner. Res. 2011;26:229–238. doi: 10.1002/jbmr.320. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

26. Uda Y., Azab E., Sun N., Shi C., Pajevic P.D. Osteocyte mechanobiology. Curr. Osteoporos. Rep. 2017;15:318–325. doi: 10.1007/s11914-017-0373-0. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

27. Yavropoulou M.P., Yovos J.G. The molecular basis of bone mechanotransduction. J. Musculoskelet. Neuronal Interact. 2016;16:221–236. [PMC free article] [PubMed] [Google Scholar]

28. Qin L., Liu W., Cao H., Xiao G. Molecular mechanosensors in osteocytes. Bone Res. 2020;8:23–24. doi: 10.1038/s41413-020-0099-y. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

29. Ma Y.V., Xu L., Mei X., Middleton K., You L. Mechanically stimulated osteocytes reduce the bone-metastatic potential of breast cancer cells in vitro by signaling through endothelial cells. J. Cell. Biochem. 2019;120:7590–7601. doi: 10.1002/jcb.28034. [PubMed] [CrossRef] [Google Scholar]

30. Verbruggen S.W., Thompson C.L., Duffy M.P., Lunetto S., Nolan J., Pearce O.M.T., Jacobs C.R., Knight M.M. Mechanical stimulation modulates osteocyte regulation of cancer cell phenotype. Cancers. 2021;13:2906. doi: 10.3390/cancers13122906. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

31. Ma Y.H.V., Lam C., Dalmia S., Gao P., Young J., Middleton K., Liu C., Xu H., You L. Mechanical regulation of breast cancer migration and apoptosis via direct and indirect osteocyte signaling. J. Cell. Biochem. 2018;119:5665–5675. doi: 10.1002/jcb.26745. [PubMed] [CrossRef] [Google Scholar]

32. Dwivedi A., Kiely P.A., Hoey D.A. Mechanically stimulated osteocytes promote the proliferation and migration of breast cancer cells via a potential CXCL1/2 mechanism. Biochem. Biophys. Res. Commun. 2021;534:14–20. doi: 10.1016/j.bbrc.2020.12.016. [PubMed] [CrossRef] [Google Scholar]

33. Zhou J.Z., Riquelme M.A., Gu S., Kar R., Gao X., Sun L., Jiang J.X. Osteocytic connexin hemichannels suppress breast cancer growth and bone metastasis. Oncogene. 2016;35:5597–5607. doi: 10.1038/onc.2016.101. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

34. Reymond N., d’Água B. B., Ridley A.J. Crossing the endothelial barrier during metastasis. Nat. Rev. Cancer. 2013;13:858–870. doi: 10.1038/nrc3628. [PubMed] [CrossRef] [Google Scholar]

35. Mei X., Middleton K., Shim D., Wan Q., Xu L., Ma Y.H.V., Devadas D., Walji N., Wang L., Young E.W.K., You L. Microfluidic platform for studying osteocyte mechanoregulation of breast cancer bone metastasis. Integr. Biol. 2019;11:119–129. doi: 10.1093/intbio/zyz008. [PubMed] [CrossRef] [Google Scholar]

36. Olcum M., Ozcivici E. Daily application of low magnitude mechanical stimulus inhibits the growth of MDA-MB-231 breast cancer cells in vitro. Cancer Cell Int. 2014;14:102–108. doi: 10.1186/s12935-014-0102-z. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

37. Yi X., Wright L.E., Pagnotti G.M., Uzer G., Powell K.M., Wallace J.M., Sankar U., Rubin C.T., Mohammad K., Guise T.A., Thompson W.R. Mechanical suppression of breast cancer cell invasion and paracrine signaling to osteoclasts requires nucleo-cytoskeletal connectivity. Bone Res. 2020;8:40. doi: 10.1038/s41413-020-00111-3. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

38. Lin C.-Y., Song X., Ke Y., Raha A., Wu Y., Wasi M., Wang L., Geng F., You L. Yoda1 enhanced low-magnitude high-frequency vibration on osteocytes in regulation of MDA-MB-231 breast cancer cell migration. Cancers. 2022;14:3395. doi: 10.3390/cancers14143395. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

39. Bersini S., Jeon J.S., Dubini G., Arrigoni C., Chung S., Charest J.L., Moretti M., Kamm R.D. A microfluidic 3D invitro model for specificity of breast cancer metastasis to bone. Biomaterials. 2014;35:2454–2461. doi: 10.1016/j.biomaterials.2013.11.050. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

40. Jeon J.S., Bersini S., Gilardi M., Dubini G., Charest J.L., Moretti M., Kamm R.D. Human 3D vascularized organotypic microfluidic assays to study breast cancer cell extravasation. Proc. Natl. Acad. Sci. USA. 2015;112:214–219. doi: 10.1073/pnas. 1501426112. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

41. Lau E., Al-Dujaili S., Guenther A., Liu D., Wang L., You L. Effect of low-magnitude, high-frequency vibration on osteocytes in the regulation of osteoclasts. Bone. 2010;46:1508–1515. doi: 10.1016/j.bone.2010.02.031. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

42. Fiszer-Kierzkowska A., Vydra N., Wysocka-Wycisk A., Kronekova Z., Jarząb M., Lisowska K.M., Krawczyk Z. Liposome-based DNA carriers may induce cellular stress response and change gene expression pattern in transfected cells. BMC Mol. Biol. 2011;12:27. doi: 10.1186/1471-2199-12-27. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

43. Cheung W.Y., Liu C., Tonelli-Zasarsky R.M.L., Simmons C.A., You L. Osteocyte apoptosis is mechanically regulated and induces angiogenesis in vitro. J. Orthop. Res. 2011;29:523–530. doi: 10.1002/jor.21283. [PubMed] [CrossRef] [Google Scholar]

44. Prasadam I., Zhou Y., Du Z., Chen J., Crawford R. , Xiao Y. Osteocyte-induced angiogenesis via VEGF-MAPK-dependent pathways in endothelial cells. Mol. Cell. Biochem. 2014;386:15–25. doi: 10.1007/s11010-013-1840-2. [PubMed] [CrossRef] [Google Scholar]

45. Syeda R., Xu J., Dubin A.E., Coste B., Mathur J., Huynh T., Matzen J., Lao J., Tully D.C., Engels I.H., et al. Chemical activation of the mechanotransduction channel Piezo1. Elife. 2015;4:1–11. doi: 10.7554/eLife.07369. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

46. Dombroski J.A., Hope J.M., Sarna N.S., King M.R. Channeling the force: piezo1 mechanotransduction in cancer metastasis. Cells. 2021;10:2815. doi: 10.3390/cells10112815. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

47. Friedrich E.E., Hong Z., Xiong S., Zhong M., Di A., Rehman J., Komarova Y.A., Malik A.B. Endothelial cell Piezo1 mediates pressure-induced lung vascular hyperpermeability via disruption of adherens junctions. Proc. Natl. Acad. Sci. USA. 2019;116:12980–12985. doi: 10.1073/pnas. 1902165116. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

48. O’Callaghan P., Engberg A., Fatsis-Kavalopoulos N., Sanchez G., Idevall-Hagren O., Kreuger J. Piezo1 activation attenuates thrombin-induced blebbing in breast cancer cells. bioRxiv. 2020 doi: 10.1101/2020.04.30.068338. Preprint at. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

49. Li C., Rezania S., Kammerer S., Sokolowski A., Devaney T., Gorischek A., Jahn S., Hackl H., Groschner K., Windpassinger C., et al. Piezo1 forms mechanosensitive ion channels in the human MCF-7 breast cancer cell line. Sci. Rep. 2015;5:8364–8369. doi: 10.1038/srep08364. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

50. O’Carrigan B., Wong M.H., Willson M.L., Stockler M.R., Pavlakis N., Goodwin A. Bisphosphonates and other bone agents for breast cancer. Cochrane Database Syst. Rev. 2017;10:CD003474. doi: 10.1002/14651858.CD003474.pub4. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

51. Zekri J. , Mansour M., Karim S.M. The anti-tumour effects of zoledronic acid. J. Bone Oncol. 2014;3:25–35. doi: 10.1016/j.jbo.2013.12.001. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

52. Senaratne S.G., Pirianov G., Mansi J.L., Arnett T.R., Colston K.W. Bisphosphonates induce apoptosis in human breast cancer cell lines. Br. J. Cancer. 2000;82:1459–1468. doi: 10.1054/bjoc.1999.1131. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

53. Liu H., Wang S.H., Chen S.C., Chen C.Y., Lin T.M. Zoledronic acid blocks the interaction between breast cancer cells and regulatory T-cells. BMC Cancer. 2019;19:176. doi: 10.1186/s12885-019-5379-9. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

54. Rachner T.D., Singh S.K., Schoppet M., Benad P., Bornhäuser M., Ellenrieder V., Ebert R., Jakob F., Hofbauer L.C. Zoledronic acid induces apoptosis and changes the TRAIL/OPG ratio in breast cancer cells. Cancer Lett. 2010;287:109–116. doi: 10.1016/j.canlet.2009.06.003. [PubMed] [CrossRef] [Google Scholar]

55. Hiraga T., Williams P.J., Ueda A., Tamura D., Yoneda T. Zoledronic acid inhibits visceral metastases in the 4T1/luc mouse breast cancer model. Clin. Cancer Res. 2004;10:4559–4567. doi: 10.1158/1078-0432.CCR-03-0325. [PubMed] [CrossRef] [Google Scholar]

56. Zhou J.Z., Riquelme M.A., Gao X., Ellies L.G., Sun L.Z., Jiang J.X. Differential impact of adenosine nucleotides released by osteocytes on breast cancer growth and bone metastasis. Oncogene. 2014;34:1831–1842. doi: 10.1038/onc.2014.113. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

57. Wang W., Sarazin B.A., Kornilowicz G., Lynch M.E. Mechanically-loaded breast cancer cells modify osteocyte mechanosensitivity by secreting factors that increase osteocyte dendrite formation and downstream resorption. Front. Endocrinol. 2018;9:352–359. doi: 10.3389/fendo.2018.00352. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

58. Wright L.E., Ottewell P.D., Rucci N., Peyruchaud O., Pagnotti G.M., Chiechi A., Buijs J. T., Sterling J.A. Murine models of breast cancer bone metastasis. Bonekey Rep. 2016;5:804–811. doi: 10.1038/bonekey.2016.31. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

59. Iorns E., Drews-Elger K., Ward T.M., Dean S., Clarke J., Berry D., El Ashry D., Lippman M. A new mouse model for the study of human breast cancer metastasis. PLoS One. 2012;7:e47995. doi: 10.1371/journal.pone.0047995. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

60. Yin L., Duan J.J., Bian X.W., Yu S.C. Triple-negative breast cancer molecular subtyping and treatment progress. Breast Cancer Res. 2020;22:61. doi: 10.1186/s13058-020-01296-5. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

61. Lumachi F., Santeufemia D.A., Basso S.M. Current medical treatment of estrogen receptor-positive breast cancer. World J. Biol. Chem. 2015;6:231–239. doi: 10.4331/wjbc.v6.i3.231. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

62. Kato Y., Windle J.J., Koop B.A., Mundy G. R., Bonewald L.F. Establishment of an osteocyte-like cell line, MLO-Y4. J. Bone Miner. Res. 1997;12:2014–2023. doi: 10.1359/jbmr.1997.12.12.2014. [PubMed] [CrossRef] [Google Scholar]

63. Schmittgen T.D., Livak K.J. Analyzing real-time PCR data by the comparative CT method. Nat. Protoc. 2008;3:1101–1108. doi: 10.1038/nprot.2008.73. [PubMed] [CrossRef] [Google Scholar]

64. Liu C., Zhao Y., Cheung W.Y., Gandhi R., Wang L., You L. Effects of cyclic hydraulic pressure on osteocytes. Bone. 2010;46:1449–1456. doi: 10.1016/j.bone.2010.02.006. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

65. Bischel L.L., Young E.W.K., Mader B.R., Beebe D.J. Tubeless microfluidic angiogenesis assay with three-dimensional endothelial-lined microvessels. Biomaterials. 2013;34:1471–1477. doi: 10.1016/j.biomaterials.2012.11.005. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

Physical Exercise with or without Whole-Body Vibration in Breast Cancer Patients Suffering from Aromatase Inhibitor—Induced Musculoskeletal Symptoms: A Pilot Randomized Clinical Study

1. De Sire A., Losco L., Cigna E., Lippi L., Gimigliano F., Gennari A., Cisari C., Chen H.C., Fusco N., Invernizzi M. Three-dimensional laser scanning as a reliable and reproducible diagnostic tool in breast cancer related lymphedema rehabilitation: A proof-of-principle study. Eur. Rev. Med. Pharmacol. Sci. 2020;24:4476–4485. doi: 10.26355/eurrev_202004_21030. [PubMed] [CrossRef] [Google Scholar]

2. De Sire A., Losco L., Cisari C., Gennari A., Boldorini R., Fusco N., Cigna E., Invernizzi M. Axillary web syndrome in women after breast cancer surgery referred to an Oncological Rehabilitation Unit: Which are the main risk factors? A retrospective case-control study. Eur. Rev. Med. Pharmacol. Sci. 2020;24:8028–8035. doi: 10.26355/eurrev_202008_22486. [PubMed] [CrossRef] [Google Scholar]

3. Invernizzi M., Kim J., Fusco N. Editorial: Quality of Life in Breast Cancer Patients and Survivors. Front. Oncol. 2020;10:620574. doi: 10.3389/fonc.2020.620574. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

4. Grizzi G., Ghidini M., Botticelli A., Tomasello G., Ghidini A., Grossi F., Fusco N., Cabiddu M., Savio T., Petrelli F. Strategies for Increasing the Effectiveness of Aromatase Inhibitors in Locally Advanced Breast Cancer: An Evidence-Based Review on Current Options. Cancer Manag. Res. 2020;ume 12:675–686. doi: 10.2147/CMAR.S202965. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

5. Molehin D., Rasha F., Rahman R.L., Pruitt K. Regulation of aromatase in cancer. Mol. Cell. Biochem. 2021;476:2449–2464. doi: 10.1007/s11010-021-04099-0. [PubMed] [CrossRef] [Google Scholar]

6. de Sire A., Ferrillo M., Gennari A., Cisari C., Pasqua S., Bonda P.L.F., Invernizzi M., Migliario M. Bone health, vitamin D status and oral hygiene screening in breast cancer women before starting osteoporosis treatment: A cross-sectional study. J. Biol. Regul. Homeost. Agents. 2021;35:397–402. [PubMed] [Google Scholar]

7. Scaturro D., de Sire A., Terrana P., Curci C., Vitagliani F., Falco V., Cuntrera D. , Iolascon G., Mauro G.L. Early Denosumab for the prevention of osteoporotic fractures in breast cancer women undergoing aromatase inhibitors: A case-control retrospective study. J. Back Musculoskelet. Rehabil. 2021:1–6. doi: 10.3233/BMR-210012. Preprint. [PubMed] [CrossRef] [Google Scholar]

8. Crew K.D., Capodice J.L., Greenlee H., Brafman L., Fuentes D., Awad D., Tsai W.Y., Hershman D.L. Randomized, Blinded, Sham-Controlled Trial of Acupuncture for the Management of Aromatase Inhibitor–Associated Joint Symptoms in Women with Early-Stage Breast Cancer. J. Clin. Oncol. 2010;28:1154–1160. doi: 10.1200/JCO.2009.23.4708. [PubMed] [CrossRef] [Google Scholar]

9. Dos Santos B.S., Bordignon C., Rosa D.D. Managing Common Estrogen Deprivation Side Effects in HR+ Breast Cancer: An Evidence-Based Review. Curr. Oncol. Rep. 2021;23:63. doi: 10.1007/s11912-021-01055-5. [PubMed] [CrossRef] [Google Scholar]

10. Baum M., Budzar A.U., Cuzick J., Forbes J., Houghton J.H., Klijn J.G.M., Sahmoud T. ATAC Trialists’ Group Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: First results of the ATAC randomised trial. Lancet. 2002;359:2131–2139. doi: 10.1016/s0140-6736(02)09088-8. [PubMed] [CrossRef] [Google Scholar]

11. Coombes R.C., Hall E., Gibson L.J., Paridaens R., Jassem J., DeLozier T., Jones S.E., Alvarez I., Bertelli G., Ortmann O., et al. A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast Cancer. N. Engl. J. Med. 2004;350:1081–1092. doi: 10.1056/NEJMoa040331. [PubMed] [CrossRef] [Google Scholar]

12. Crew K.D., Greenlee H., Capodice J., Raptis G., Brafman L., Fuentes D., Sierra A., Hershman D.L. Prevalence of Joint Symptoms in Postmenopausal Women Taking Aromatase Inhibitors for Early-Stage Breast Cancer. J. Clin. Oncol. 2007;25:3877–3883. doi: 10.1200/JCO.2007.10.7573. [PubMed] [CrossRef] [Google Scholar]

13. Murphy C.C., Bartholomew L.K., Carpentier M.Y., Bluethmann S.M., Vernon S.W. Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: A systematic review. Breast Cancer Res. Treat. 2012;134:459–478. doi: 10.1007/s10549-012-2114-5. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

14. Migliaccio S., de Sire A., Marocco C., Fornari R., Paoletta M., Greco E.A., Amar I.D., Moretti A., Ronzoni S., Gimigliano F., et al. Approach in aromatase inhibitors—Induced osteoporosis: Results from an Italian multicenter observational study. Clin. Cases Miner. Bone Metab. 2018;15:334–339. [Google Scholar]

15. Sestak I., Cuzick J., Sapunar F., Eastell R., Forbes J.F., Bianco A.R., Buzdar A.U. Risk factors for joint symptoms in patients enrolled in the ATAC trial: A retrospective, exploratory analysis. Lancet Oncol. 2008;9:866–872. doi: 10.1016/S1470-2045(08)70182-7. [PubMed] [CrossRef] [Google Scholar]

16. Nardin S., Mora E., Varughese F.M., D’Avanzo F. , Vachanaram A.R., Rossi V., Saggia C., Rubinelli S., Gennari A. Breast Cancer Survivorship, Quality of Life, and Late Toxicities. Front. Oncol. 2020;10:864. doi: 10.3389/fonc.2020.00864. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

17. Irwin M.L., Cartmel B., Gross C.P., Ercolano E., Li F., Yao X., Fiellin M., Capozza S., Rothbard M., Zhou Y., et al. Randomized Exercise Trial of Aromatase Inhibitor–Induced Arthralgia in Breast Cancer Survivors. J. Clin. Oncol. 2015;33:1104–1111. doi: 10.1200/JCO.2014.57.1547. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

18. Greenlee H., Crew K.D., Shao T., Kranwinkel G., Kalinsky K., Maurer M., Brafman L., Insel B., Tsai W.Y., Hershman D.L. Phase II study of glucosamine with chondroitin on aromatase inhibitor-associated joint symptoms in women with breast cancer. Support. Care Cancer. 2012;21:1077–1087. doi: 10.1007/s00520-012-1628-z. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

19. Khan Q.J., Reddy P. S., Kimler B.F., Sharma P., Baxa S.E., O’Dea A.P., Klemp J.R., Fabian C.J. Effect of vitamin D supplementation on serum 25-hydroxy vitamin D levels, joint pain, and fatigue in women starting adjuvant letrozole treatment for breast cancer. Breast Cancer Res. Treat. 2009;119:111–118. doi: 10.1007/s10549-009-0495-x. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

20. Oh B., Kimble B., Costa D.S.J., Davis E., McLean A., Orme K., Beith J. Acupuncture for Treatment of Arthralgia Secondary to Aromatase Inhibitor Therapy in Women with Early Breast Cancer: Pilot Study. Acupunct. Med. 2013;31:264–271. doi: 10.1136/acupmed-2012-010309. [PubMed] [CrossRef] [Google Scholar]

21. Arem H., Sorkin M., Cartmel B., Fiellin M., Capozza S., Harrigan M., Ercolano E., Zhou Y., Sanft T., Gross C., et al. Exercise adherence in a randomized trial of exercise on aromatase inhibitor arthralgias in breast cancer survivors: The Hormones and Physical Exercise (HOPE) study. J. Cancer Surviv. 2016;10:654–662. doi: 10.1007/s11764-015-0511-6. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

22. Dong Y., Wang H., Zhu Y., Chen B., Zheng Y., Liu X., Qiao J., Wang X. Effects of whole-body vibration exercise on lumbar-abdominal muscles activation for patients with chronic low back pain. BMC Sports Sci. Med. Rehabil. 2020;12:78. doi: 10.1186/s13102-020-00226-4. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

23. Rabini A., de Sire A., Marzetti E., Gimigliano R., Ferriero G., Piazzini D.B., Iolascon G., Gimigliano F. Effects of focal muscle vibration on physical functioning in patients with knee osteoarthritis: A randomized controlled trial. Eur. J. Phys. Rehabil. Med. 2015;51:513–520. [PubMed] [Google Scholar]

24. Dong Y., Wang W., Zheng J., Chen S., Qiao J., Wang X. Whole Body Vibration Exercise for Chronic Musculoskeletal Pain: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Arch. Phys. Med. Rehabil. 2019;100:2167–2178. doi: 10.1016/j.apmr.2019. 03.011. [PubMed] [CrossRef] [Google Scholar]

25. Zhang J., Wang R., Zheng Y., Xu J., Wu Y., Wang X. Effect of Whole-Body Vibration Training on Muscle Activation for Individuals with Knee Osteoarthritis. BioMed. Res. Int. 2021;2021:6671390. doi: 10.1155/2021/6671390. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

26. Lai C.-C., Tu Y.-K., Wang T.-G., Huang Y.-T., Chien K.-L. Effects of resistance training, endurance training and whole-body vibration on lean body mass, muscle strength and physical performance in older people: A systematic review and network meta-analysis. Age Ageing. 2018;47:367–373. doi: 10.1093/ageing/afy009. [PubMed] [CrossRef] [Google Scholar]

27. Alam M.M., Khan A.A., Farooq M. Effect of whole-body vibration on neuromuscular performance: A literature review. Work. 2018;59:571–583. doi: 10.3233/WOR-182699. [PubMed] [CrossRef] [Google Scholar]

28. Cardinale M.B.C. The use of vibration as an exercise intervention. Exerc. Sport Sci. Rev. 2003;31:3–7. doi: 10.1097/00003677-200301000-00002. [PubMed] [CrossRef] [Google Scholar]

29. Sitjà-Rabert M., Rigau D., Fort-Vanmeerhaeghe A., Romero-Rodríguez D., Subirana M.B., Bonfill X. Efficacy of whole-body vibration exercise in older people: A systematic review. Disabil. Rehabil. 2012;34:883–893. doi: 10.3109/09638288.2011.626486. [PubMed] [CrossRef] [Google Scholar]

30. Sañudo B., De Hoyo M., Carrasco L., McVeigh J.G., Corral J., Cabeza R., Rodríguez C., Oliva A. The effect of 6-week exercise programme and whole-body vibration on strength and quality of life in women with fibromyalgia: A randomised study. Clin. Exp. Rheumatol. 2010;28:S40–S45. [PubMed] [Google Scholar]

31. Micke F., Weissenfels A., Wirtz N., von Stengel S., Dörmann U., Kohl M., Kleinöder H., Donath L., Kemmler W. Similar Pain Intensity Reductions and Trunk Strength Improvements Following Whole-Body Electromyostimulation vs. Whole-Body Vibration vs. Conventional Back-Strengthening Training in Chronic Non-specific Low Back Pain Patients: A Three-Armed Randomized Controlled Trial. Front. Physiol. 2021;12:664991. [PMC free article] [PubMed] [Google Scholar]

32. Streckmann F., Balke M., Lehmann H.C., Rustler V., Koliamitra C., Elter T., Hallek M., Leitzmann M., Steinmetz T., Heinen P., et al. The preventive effect of sensorimotor- and vibration exercises on the onset of Oxaliplatin- or vinca-alkaloid induced peripheral neuropathies—STOP. BMC Cancer. 2018;18:62. doi: 10.1186/s12885-017-3866-4. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

33. Baker M.K., Peddle-McIntyre C., Galvao D., Hunt C., Spry N., Newton R.U. Whole Body Vibration Exposure on Markers of Bone Turnover, Body Composition, and Physical Functioning in Breast Cancer Patients Receiving Aromatase Inhibitor Therapy: A Randomized Controlled Trial. Integr. Cancer Ther. 2018;17:968–978. doi: 10.1177/1534735418781489. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

34. Roberts K., Rickett K., Feng S., Vagenas D., Woodward N. Exercise therapies for preventing or treating aromatase inhibitor-induced musculoskeletal symptoms in early breast cancer. Cochrane Database Syst. Rev. 2020;1:CD012988. doi: 10.1002/14651858.CD012988.pub2. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

35. Association W.M. World Medical Association Declaration of Helsinki: Ethical principles for medical research involving human subjects. JAMA. 2013;310:2191–2194. [PubMed] [Google Scholar]

36. Skinner J.S., Hutsler E., Bergsteinova V., Buskirk E.R. The validity and reliability of a rating scale of perceived exertion. Med. Sci. Sports Exerc. 1973;5:94–96. doi: 10.1249/00005768-197300520-00018. [PubMed] [CrossRef] [Google Scholar]

37. Jakobsen L.H., Rask I.K., Kondrup J. Validation of handgrip strength and endurance as a measure of physical function and quality of life in healthy subjects and patients. Nutrition. 2010;26:542–550. doi: 10.1016/j.nut.2009.06.015. [PubMed] [CrossRef] [Google Scholar]

38. Salaffi F., Leardini G., Canesi B., Mannoni A., Fioravanti A., Caporali R., Lapadula G., Punzi L. Reliability and validity of the Western Ontario and McMaster Universities (WOMAC) Osteoarthritis Index in Italian patients with osteoarthritis of the knee. Osteoarthr. Cartil. 2003;11:551–560. doi: 10.1016/S1063-4584(03)00089-X. [PubMed] [CrossRef] [Google Scholar]

39. Amatachaya S., Kwanmongkolthong M., Thongjumroon A., Boonpew N., Amatachaya P., Saensook W., Thaweewannakij T., Hunsawong T. Influence of timing protocols and distance covered on the outcomes of the 10-meter walk test. Physiother. Theory Pract. 2020;36:1348–1353. doi: 10.1080/09593985.2019.1570577. [PubMed] [CrossRef] [Google Scholar]

40. ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories ATS statement: Guidelines for the six-minute walk test. Am. J. Respir. Crit. Care Med. 2002;166:111–117. doi: 10.1164/ajrccm.166.1.at1102. [PubMed] [CrossRef] [Google Scholar]

41. Aaronson N.K., Ahmedzai S., Bergman B., Bullinger M., Cull A., Duez N.J., Filiberti A., Flechtner H., Fleishman S.B., De Haes J.C., et al. The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in Oncology. J. Natl. Cancer Inst. 1993;85:365–376. doi: 10.1093/jnci/85.5.365. [PubMed] [CrossRef] [Google Scholar]

42. Meisingset I., Stensdotter A.K., Woodhouse A., Vasseljen O. Predictors for global perceived effect after physiotherapy in patients with neck pain: An observational study. Physiotherapy. 2017;104:400–407. doi: 10.1016/j.physio.2017.01.007. [PubMed] [CrossRef] [Google Scholar]

43. Hershman D.L., Shao T., Kushi L.H., Buono D., Tsai W.Y., Fehrenbacher L., Kwan M., Gomez S.L., Neugut A.I. Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res. Treat. 2010;126:529–537. doi: 10.1007/s10549-010-1132-4. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

44. Geirsdottir O.G., Arnarson A., Briem K., Ramel A., Jonsson P.V., Thorsdottir I. Effect of 12-Week Resistance Exercise Program on Body Composition, Muscle Strength, Physical Function, and Glucose Metabolism in Healthy, Insulin-Resistant, and Diabetic Elderly Icelanders. J. Gerontol. Ser. A Biomed. Sci. Med. Sci. 2012;67:1259–1265. doi: 10.1093/gerona/gls096. [PubMed] [CrossRef] [Google Scholar]

45. Hassan B.H., Hewitt J., Keogh J.W., Bermeo S., Duque G., Henwood T.R. Impact of resistance training on sarcopenia in nursing care facilities: A pilot study. Geriatr. Nurs. 2015;37:116–121. doi: 10.1016/j.gerinurse.2015.11.001. [PubMed] [CrossRef] [Google Scholar]

46. Lee M., Carroll T.J. Cross education: Possible mechanisms for the contralateral effects of unilateral resistance training. Sports Med. 2007;37:1–14. doi: 10.2165/00007256-200737010-00001. [PubMed] [CrossRef] [Google Scholar]

47. Zheng Y.L., Zhang Z.J., Peng M.S., Hu H.Y., Zhang J., Wang X.Q. Whole-body vibration exercise for low back pain: A meta-analysis protocol of randomized controlled trial. Medicine. 2018;97:e12534. doi: 10.1097/MD.0000000000012534. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

48. Zafar H., Alghadir A., Anwer S., Al-Eisa E. Therapeutic Effects of Whole-Body Vibration Training in Knee Osteoarthritis: A Systematic Review and Meta-Analysis. Arch. Phys. Med. Rehabil. 2015;96:1525–1532. doi: 10.1016/j.apmr.2015.03.010. [PubMed] [CrossRef] [Google Scholar]

49. Verhulst A.L., Savelberg H.H., Vreugdenhil G., Mischi M., Schep G. Whole-body vibration as a modality for the rehabilitation of peripheral neuropathies: Implications for cancer survivors suffering from chemotherapy-induced peripheral neuropathy. Oncol. Rev. 2015;9:263. doi: 10.4081/oncol.2015.263. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

50. Bidonde J., Busch A.J., van der Spuy S.P., Tupper S., Kim S.Y., Boden C. Whole body vibration exercise training for fibromyalgia. Cochrane Database Syst. Rev. 2017;9:CD011755. doi: 10.1002/14651858.CD011755.pub2. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

51. Tonorezos E.S., Ford J.S., Wang L., Pt K.K.N., Yasui Y., Leisenring W., Sklar C.A., Robison L.L., Oeffinger K.C., Nathan P.C., et al. Impact of exercise on psychological burden in adult survivors of childhood cancer: A report from the Childhood Cancer Survivor Study. Cancer. 2019;125:3059–3067. doi: 10.1002/cncr.32173. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

52. Melzack R.W.P. Pain mechanisms: A new theory. Science. 1965;150:971–979. doi: 10.1126/science.150.3699.971. [PubMed] [CrossRef] [Google Scholar]

53. Longe S.E., Wise R., Bantick S., Lloyd D., Johansen-Berg H., McGlone F., Tracey I. Counter-stimulatory effects on pain perception and processing are significantly altered by attention: An fMRI study. Neuroreport. 2001;12:2021–2025. doi: 10.1097/00001756-200107030-00047. [PubMed] [CrossRef] [Google Scholar]

54. Moggio L., de Sire A., Marotta N., Demeco A., Ammendolia A. Vibration therapy role in neurological diseases rehabilitation: An umbrella review of systematic reviews. Disabil. Rehabil. 2021;5:1–9. doi: 10.1080/09638288.2021.1946175. [PubMed] [CrossRef] [Google Scholar]

55. Jamal A., Ahmad I., Ahamed N., Azharuddin M., Alam F., Hussain M.E. Whole body vibration showed beneficial effect on pain, balance measures and quality of life in painful diabetic peripheral neuropathy: A randomized controlled trial. J. Diabetes Metab. Disord. 2019;19:61–69. doi: 10.1007/s40200-019-00476-1. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

56. Coghill R.C.T.J., Evans A.C., Meyer E., Gjedde A., Bushnell M.C., Duncan G.H. Distributed processing of pain and vibration by the human brain. J. Neurosci. 1994;14:4095–4108. doi: 10.1523/JNEUROSCI.14-07-04095.1994. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

Neuralgia in the region of the heart symptoms and signs

  • Main
  • Blog
  • What is neuralgia in the region of the heart, what are the symptoms and treatment?

Content:

  • Causes

  • Symptoms of intercostal neuralgia in the region of the heart

  • What to do with neuralgia in the region of the heart

  • How to treat neuralgia in the region of the heart

Symptoms of neuralgia in the region of the heart resemble signs of dangerous cardiovascular pathologies like coronary disease or heart attack. But despite the similarity of the signs, neuralgia and pain in the heart area are not related to CVD. The disease is treated not by a cardiologist, but by a neurologist.

Causes

Neuralgia can occur for various reasons. Most frequent:

  • Malignant or benign growth that presses on the nerves.
  • Diseases of the spine, pinched nerves by a hernia.
  • Cysts.
  • Herpes.
  • Severe curvature of the spine.
  • Heavy physical activity, including sports.
  • Traumatic injuries.
  • Chest surgery.
  • Lung cancer.
  • SARS.
  • Forced bed rest.
  • Congenital malformations.
  • Disorders of the blood supply, malnutrition of the nerves.
  • Period of rapid growth in children.
  • Long stay in the cold and piercing wind, local hypothermia.
  • Staying in an uncomfortable position due to the nature of the work.
  • Radio frequency therapy.

Symptoms of neuralgia in the region of the heart resemble signs of dangerous cardiovascular pathologies like coronary disease or heart attack. But despite the similarity of the signs, neuralgia and pain in the heart area are not related to CVD. The disease is treated not by a cardiologist, but by a neurologist.

Risk factors:

  • Autoimmune diseases.
  • Immunodeficiencies.
  • SD.
  • HCV infection.
  • Nephrological diseases.
  • Alcoholism.
  • Passive way of life.
  • Stress.
  • Neuroses and other functional disorders of the nervous system.
  • Old age.

Complications of nerve block may include respiratory failure, pneumothorax, coughing up blood, tissue death, infection, but these conditions are rare. The main problem is delivered by strong, burning, shooting pains.

Symptoms of intercostal neuralgia in the region of the heart

Signs of pathology can be mistaken for cardiological diseases and respiratory diseases, women suspect breast cancer. After a long cold with a cough, myofascial syndrome occurs, in which pain can resemble signs of neuralgia in the region of the heart.

Reasonable vigilance does not hurt: vigilant patients seek medical help more often. Nevertheless, you should not panic ahead of time: as you know, stress has a destructive effect and provokes CVD.

Differences between neuralgia and other diseases:

  • Other symptoms appear in CVD. Of course, there are also silent heart attacks, when there is no pain, but if the pain syndrome appears, it is accompanied by: sweating, shortness of breath, poor exercise tolerance, increased blood pressure. Symptoms of intercostal neuralgia on the left in the region of the heart are not accompanied by such signs.
  • In heart disease, pain usually affects the left side of the body: chest, shoulder blade, collarbone, shoulder, back and even jaw. Moreover, the pain is often spilled, it is impossible to pinpoint exactly where it hurts. With neuralgia, pain is clearly localized in the chest area, and if other nerves are also affected, then in the area of ​​\u200b\u200bthe stomach or scapula.
  • Nitroglycerin is effective in most CVDs. If the medicine is taken for neuralgia, it will not have an effect.
  • The onset of neuralgia is not abrupt: tingling sensations serve as precursors, the rib and sternum may become numb.
  • The pain is manifested by spasms, the character is different, but most often these sensations are difficult to confuse: they resemble a pinched nerve, they manifest as lumbago, as if from an electric shock.
  • In motion the symptoms are aggravated, in rest they decrease, but do not disappear altogether. With CVD, attacks last several minutes, with neuralgia, the chest and rib continue to ache until treatment is selected.
  • With CVD, swelling of the face and lower extremities may appear, with intercostal neuralgia, the area swells along the nerve.
  • With CVD, patients complain of shortness of breath, with neuralgia – of breathlessness.
  • Patients with cardiac diseases sweat a lot, fever may be observed, this is not characteristic of neuralgia.

Other manifestations indicate neuralgia: pallor or redness, the skin at the site of the lesion may lose sensitivity.

How to treat neuralgia in the region of the heart

If symptoms of neuralgia in the region of the heart appear, only a doctor should prescribe treatment. Independent intramuscular administration of painkillers can be dangerous, so it is better to immediately contact a neurologist who will help you choose the best therapy.

At home, you can do a simple test: when you bend over, you will try to reduce the load on the non-affected side, so the bends will be on the healthy half. With CVD, for example, angina pectoris, the symptoms will increase during physical exertion, but if the pain is provoked by turns of the body, coughing, sneezing, this is most likely neuralgia.

How to treat neuralgia in the region of the heart

To detect neuralgia, the patient is prescribed CT, X-ray, studies with contrast. After differential diagnosis, painkillers, anti-inflammatory drugs, vitamin therapy, and sedatives are prescribed. A number of patients are prescribed manual therapy. An operation to remove nerves is very rare, and is indicated if conservative methods fail to achieve the desired result, the patient is forced to limit himself in movements, which significantly affects the quality of life.

Neuralgia responds well to treatment: if you have already been treated before, but are not satisfied with the result, you may need further examination. The reason may be in previously undiscovered hernias, tumors, etc. Drug therapy is prescribed with caution during pregnancy. Priority is given to physiotherapy exercises, not medicines.

Neuralgia can be confused with CVD, and patients with chest pain require careful evaluation to rule out a life-threatening condition. Make an appointment at the Chekhov Vascular Center of the Moscow Region and do not endure pain.

8-800-444-49-59
Appointment for consultation, research

Beregovaya st., 36A, Chekhov, Moscow region, Russia, 142301

This email address is being protected from spambots. You must have JavaScript enabled to view.

Mon-Sun – Around the clock

Osteochondrosis of the thoracic region – symptoms, causes, signs, diagnosis and treatment in the “SM-Clinic”

This disease is treated by Neurologist

  • What is osteochondrosis of the thoracic spine?
  • Symptoms of osteochondrosis of the thoracic spine
  • Causes of osteochondrosis of the thoracic spine
  • Diagnosis of osteochondrosis of the thoracic spine
  • Conservative treatment
  • Surgical treatment
  • Doctors

Symptoms of osteochondrosis of the thoracic spine

Osteochondrosis of the thoracic spine has the least pronounced symptoms in comparison with other forms of osteochondrosis. The main manifestation of the disease is pain in the chest area, manifested during exercise or prolonged stay in one position. In this case, pain can be transmitted to internal organs. The pain often worsens at night and during sleep.

In addition, with the disease, there is a change in the temperature of the upper and lower extremities. The patient may have cold hands and feet, dry skin, and numbness.

Other symptoms of thoracic osteochondrosis:

  • pain between the shoulder blades, aggravated by raising the arms, bending the body;
  • soreness between the ribs when walking and moving the body, aggravated by deep inspiration and expiration;
  • feeling of stiffness and pressure in the thoracic region.

Non-specific symptoms of pathology can also be distinguished:

  • numbness and tingling of skin areas;
  • peeling of the skin of the limbs, brittle nails;
  • disruption of the digestive tract.

Let us dwell on two important manifestations of thoracic osteochondrosis – dorsago and dorsalgia.

Under the dorsago understand a sharp sharp pain in the sternum, usually occurring with a long stay in one position and aggravated by rotation of the body. The attack is often accompanied by difficulty breathing.

Dorsalgia is called mild pain in the area of ​​damaged intervertebral discs. Soreness begins gradually and lasts for 2-3 weeks, periodically intensifying and subsiding. In this case, the patient may experience a lack of air. The detection of any of these symptoms is a good reason to visit a doctor.

Causes of osteochondrosis of the thoracic spine

Osteochondrosis of the thoracic spine is less common than other forms of this disease – cervical, lumbar and sacral osteochondrosis. The reason for this lies in the lower mobility of the thoracic region, its protection by ribs and a developed muscular corset. In this regard, this form of pathology rarely occurs due to excessive physical exertion.

Also isolated additional factors contributing to the development of osteochondrosis:

  • sedentary lifestyle, sedentary work;
  • chest trauma;
  • hormonal disorders;
  • scoliosis, kyphosis and other posture disorders;
  • hereditary predisposition;
  • autoimmune diseases;
  • endocrine diseases, metabolic disorders.

Get advice

If you experience these symptoms, we recommend that you make an appointment with your doctor. Timely consultation will prevent negative consequences for your health.

To learn more about the disease, prices for treatment and sign up for a consultation with a specialist, you can call:

+7 (495) 292-39-72

Request a call back
Book online

Why SM-Clinic?

1

Treatment is carried out in accordance with clinical guidelines

2

Comprehensive assessment of the nature of the disease and treatment prognosis

3

Modern diagnostic equipment and own laboratory

4

High level of service and balanced pricing policy

Diagnosis of osteochondrosis of the thoracic spine

Osteochondrosis is a slowly progressive disease that requires timely diagnosis and treatment. Pathology can only be determined by a qualified specialist with experience in neurology and traumatology.

At the first appointment, the doctors of the medical center “SM-Clinic” examine the patient, conduct functional tests. Also, during the appointment, the doctor asks the patient about the localization of pain and the presence of other symptoms associated with the pathology of the spine. After making a preliminary diagnosis, the patient is sent for additional examinations in order to finally confirm the initial assumption.

Studies that allow the diagnosis of osteochondrosis of the thoracic region:

  • chest x-ray;
  • magnetic resonance imaging;
  • multislice computed tomography.

In addition, the following studies will help determine the causes of the development of pathology, as well as identify concomitant diseases: ultrasound of the chest and abdominal organs, ECG of the heart, duplex scanning of blood vessels, laboratory tests of blood and urine.

Treatment of thoracic osteochondrosis

There are two main options for the treatment of thoracic osteochondrosis – conservative and surgical. Therapy is used if the pathology was diagnosed in the early stages, and irreversible changes have not yet occurred in the body. An operation is necessary if conservative methods of treatment did not bring the expected result, or if the patient went to the clinic already at advanced stages.

Conservative treatment

The main task of therapeutic treatment is to stop degenerative-dystrophic processes in the intervertebral discs, relieve unpleasant symptoms and restore mobility of the thoracic spine. The following methods are used for this:

  • Medical treatment. The use of drugs can relieve severe inflammation and pain, ensure normal blood flow to the spine, and relieve spasms in the back muscles. To do this, the doctor may prescribe analgesics, anti-inflammatory drugs, muscle relaxants, chondroprotectors, etc.
  • Physiotherapy treatments. Physiotherapy techniques can reduce pain and inflammation, improve blood circulation, strengthen the muscle corset. For this purpose, the following are used: massage, electrophoresis, acupuncture, laser therapy, magnetotherapy, phonophoresis, UHF therapy, etc.
  • Therapeutic gymnastics. A well-composed set of physical exercises will allow the patient to strengthen muscles, restore spinal mobility and prevent further development of osteochondrosis.

Surgical treatment

Depending on the clinical picture of the disease, doctors select the optimal method of surgical treatment:

Microdiscectomy is a minimally invasive intervention to remove a herniated disc.

Decompression-stabilizing surgeries are used in case of “squeezing” of nerve spinal structures by a hernia. Simultaneously with decompression of the spinal root, stabilization of the spine (with implantation of a fixing system) can be performed.

The multidisciplinary medical holding “SM-Clinic” provides both therapeutic and surgical treatment of osteochondrosis of the thoracic spine. Our clinic has all the necessary conditions for comfortable and effective elimination of intervertebral disc pathologies, regardless of their severity. Trust your health to the hands of professionals!

>

Diseases referred to Neurologist

Pituitary adenoma
Amnesia
Cerebral aneurysm
Atherosclerosis of cerebral vessels
Aphasia
Insomnia
Alzheimer’s disease
Parkinson’s disease
Backache
brachycephaly
Vegetovascular dystonia (VVD)
Epstein-Barr virus
Hemianopia
Hydrocephalus
Eye migraine
Schmorl’s hernia
dysarthria
Dorsopathy
Stroke
brain cyst
Intervertebral hernia
Intercostal neuralgia
Meningitis
myasthenia gravis
Myositis
Myositis of the back muscles
Myofascial Syndrome
Narcolepsy
Neuralgia
trigeminal neuralgia
Neurasthenia
Cardiopsychoneurosis
Nervous tic
Spinal instability
Nightmares
fainting
Osteochondrosis
Osteochondrosis lumbar
Osteochondrosis of the cervical spine
Nerve damage
Polyneuropathy
Polio
Protrusions of the intervertebral discs
Radiculitis
Tourette syndrome
Chronic pelvic pain syndrome
Spinal stenosis
Enuresis
Encephalopathy

All doctors

VDNH metro station

Belorusskaya metro station

Lesnaya, d.